PhoenixDx® 2019-nCoV PCR test
PhoenixDx® 2019-nCoV, qualitative RT-PCR-based detection of 2019-nCoV.
The first step in the detection of 2019-nCoV is the conversion of viral RNA into cDNA. Afterwards, the target sequences unique for 2019-nCoV are specifically amplified with amplification monitored in real time through the use of fluorescently labelled probes: upon incorporation into the newly amplified DNA strands, the fluorophore (FAM™) is released and an increase in fluorescence signal can be observed.
Due to the intrinsic mutation rate of coronaviruses, it is possible that mutations in the target sequence occur and accumulate over time. This can lead to false-negative results with a PCR-based detection approach. PHOENIXDX® 2019-NCOV addresses this issue by using 3 detection assays on 3 different target sequences to minimize the chance of false-negative results caused by an altered target sequence.
If samples are tested negative in one or more assays, additional complementary testing may be required. The original target sequences for 2019-nCoV are included as a non-infectious target positive control (TPC) to check the integrity of the detection assays.
Samples tested positive should always be confirmed through complementary methods and additional analysis in an independent laboratory.
Frequently Asked Questions about this Reagent
A: Yes, we supply only 100% genuine in vitro diagnostic (IVD) reagents manufactured by
PhoenixDx® 2019-nCoV, qualitative RT-PCR-based detection of 2019-nCoV.
The first step in the detection of 2019-nCoV is the conversion of viral RNA into cDNA. Afterwards, the target sequences unique for 2019-nCoV are specifically amplified with amplification monitored in real time through the use of fluorescently labelled probes: upon incorporation into the newly amplified DNA strands, the fluorophore (FAM™) is released and an increase in fluorescence signal can be observed.
Due to the intrinsic mutation rate of coronaviruses, it is possible that mutations in the target sequence occur and accumulate over time. This can lead to false-negative results with a PCR-based detection approach. PHOENIXDX® 2019-NCOV addresses this issue by using 3 detection assays on 3 different target sequences to minimize the chance of false-negative results caused by an altered target sequence.
If samples are tested negative in one or more assays, additional complementary testing may be required. The original target sequences for 2019-nCoV are included as a non-infectious target positive control (TPC) to check the integrity of the detection assays.
Samples tested positive should always be confirmed through complementary methods and additional analysis in an independent laboratory.
.
A: The exact catalog ref number for this product is PCCSKU15259. Use this to verify compatibility with your clinical analyzer.
A: We manage secure cold chain logistics worldwide. Reagents requiring 2Ð8¡C or -20¡C storage are shipped in validated thermal containers with medical-grade gel packs or dry ice.
Frequently Asked Questions about this Reagent
A: Yes, we supply only 100% genuine in vitro diagnostic (IVD) reagents manufactured by Siemens Healthineers. Every kit is delivered in its original packaging with authentic batch numbers.
A: The exact catalog ref number for this Siemens Healthineers product is PCCSKU15259. Please use this number to verify compatibility with your clinical analyzer.
A: We manage secure cold chain logistics worldwide. Reagents requiring 2–8°C or -20°C storage are shipped in validated thermal containers with medical-grade gel packs or dry ice to guarantee stability upon arrival.
A: Absolutely. You can see standard pricing on reagents.store, but we offer volume-based tier pricing for laboratories and distributors. Register an account or submit an inquiry with your required volume to get a formal quote.